CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Letter: Favorable Glycemic Control with Once-Daily Insulin Degludec/Insulin Aspart after Changing from Basal Insulin in Adults with Type 2 Diabetes (Endocrinol Metab 2019; 34:382-9, Han Na Jang et al.)
Sang Youl Rhee
Endocrinol Metab. 2020;35(1):192-193.   Published online March 19, 2020
DOI: https://doi.org/10.3803/EnM.2020.35.1.192

Excel Download

Response: Favorable Glycemic Control with Once-Daily Insulin Degludec/Insulin Aspart after Changing from Basal Insulin in Adults with Type 2 Diabetes (Endocrinol Metab 2019; 34:382-9, Han Na Jang et al.)
Endocrinology and Metabolism. 2020;35(1):194   Crossref logo
Link1 Link2 Link3

Letter: Favorable Glycemic Control with Once-Daily Insulin Degludec/Insulin Aspart after Changing from Basal Insulin in Adults with Type 2 Diabetes (Endocrinol Metab 2019; 34:382-9, Han Na Jang et al.)
Endocrinology and Metabolism. 2020;35(1):192   Crossref logo
Link1 Link2 Link3

Favorable Glycemic Control with Once-Daily Insulin Degludec/Insulin Aspart after Changing from Basal Insulin in Adults with Type 2 Diabetes
Endocrinology and Metabolism. 2019;34(4):382   Crossref logo
Link1 Link2 Link3

Switching to Once-Daily Insulin Degludec/Insulin Aspart from Basal Insulin Improves Postprandial Glycemia in Patients with Type 2 Diabetes Mellitus: Randomized Controlled Trial
Diabetes & Metabolism Journal. 2020;44(4):532   Crossref logo
Link1 Link2 Link3

Superior glycaemic control with once‐daily insulin degludec/insulin aspart versus insulin glargine in Japanese adults with type 2 diabetes inadequately controlled with oral drugs: a randomized, controlled phase 3 trial
Diabetes, Obesity and Metabolism. 2013;15(9):826-832   Crossref logo
Link1 Link2 Link3 Link4

Efficacy and safety of once-daily insulin degludec/insulin aspart compared with once-daily insulin glargine in participants with Type 2 diabetes: a randomized, treat-to-target study
Diabetic Medicine. 2016;34(2):180-188   Crossref logo
Link1 Link2 Link3

Twice-daily insulin degludec/insulin aspart provides superior fasting plasma glucose control and a reduced rate of hypoglycaemia compared with biphasic insulin aspart 30 in insulin-naïve adults with Type 2 diabetes
Diabetic Medicine. 2015;33(4):497-505   Crossref logo
Link1 Link2 Link3

Insulin lispro low mixture twice daily versus basal insulin glargine once daily and prandial insulin lispro once daily in patients with type 2 diabetes requiring insulin intensification: a randomized phase IV trial
Diabetes, Obesity and Metabolism. 2014;16(10):963-970   Crossref logo
Link1

Safety and efficacy of insulin degludec/insulin aspart with bolus mealtime insulin aspart compared with standard basal-bolus treatment in people with Type 1 diabetes: 1-year results from a randomized clinical trial (BOOST® T1)
Diabetic Medicine. 2016;34(2):167-173   Crossref logo
Link1 Link2 Link3

Fast-acting insulin aspart versus insulin aspart in the setting of insulin degludec-treated type 1 diabetes: Efficacy and safety from a randomized double-blind trial
Diabetes, Obesity and Metabolism. 2018;20(12):2885-2893   Crossref logo
Link1 Link2